Darolutamide (BAY1841788) + Enzalutamide
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cerebrovascular Circulation
Conditions
Cerebrovascular Circulation
Trial Timeline
Oct 23, 2018 → Nov 5, 2019
NCT ID
NCT03704519About Darolutamide (BAY1841788) + Enzalutamide
Darolutamide (BAY1841788) + Enzalutamide is a phase 1 stage product being developed by Bayer for Cerebrovascular Circulation. The current trial status is completed. This product is registered under clinical trial identifier NCT03704519. Target conditions include Cerebrovascular Circulation.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03704519 | Phase 1 | Completed |
Competing Products
14 competing products in Cerebrovascular Circulation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM872 (zonampanel) | Astellas Pharma | Phase 2 | 52 |
| donepezil hcl | Eisai | Phase 3 | 77 |
| Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochloride | Eisai | Approved | 85 |
| ONO-2506 | Ono Pharmaceutical | Phase 2/3 | 65 |
| Abciximab | Eli Lilly | Phase 3 | 77 |
| atomoxetine + Stimulants | Eli Lilly | Pre-clinical | 23 |
| ticagrelor + ASA + Placebo+ASA | AstraZeneca | Approved | 85 |
| Valsartan | Novartis | Pre-clinical | 23 |
| Atorvastatin | Pfizer | Approved | 84 |
| Rivaroxaban | Bayer | Pre-clinical | 20 |
| Botulinum toxin type A + Placebo | Ipsen | Approved | 82 |
| Atorvastatin 20mg | Brain Biotech | Approved | 77 |
| Autologous bone marrow mononuclear cell transplantation | Brain Biotech | Phase 1 | 25 |
| Roflumilast Oral Tablet | Brain Biotech | Phase 2 | 44 |